Multivariate analysis for aGVHD, cGVHD, TRM, relapse, treatment failure, and overall survival
Outcome . | RR (95% CI) . | P . |
---|---|---|
aGVHD | ||
Mismatch related vs HLA-identical sibling | 1.57 (1.06-2.33) | .024 |
Other significant risk factors | ||
Disease stage before transplantation | ||
Advanced vs early/intermediate | 1.68 (1.09-2.60) | .020 |
ABO blood group | ||
Matched | 1.00 | .033† |
Minor mismatched | 0.42 (0.22-0.81) | .009 |
Major mismatched | 0.93 (0.61-1.42) | .733 |
cGVHD | ||
Mismatch related vs HLA-identical sibling | 0.99 (0.72-1.38) | .969 |
TRM* | ||
Mismatch related vs HLA-identical sibling | 1.75 (0.99-3.09) | .054 |
Relapse | ||
Mismatch related vs HLA-identical sibling | 0.86 (0.45-1.65) | .653 |
Other significant risk factors | ||
Disease stage before transplantation | ||
Advanced vs early/intermediate | 5.69 (2.92-11.09) | < .001 |
Disease type | ||
ALL | 1.00 | .002† |
AML | 0.75 (0.36-1.56) | .436 |
CML | 0.24 (0.09-0.59) | .002 |
MDS | 0.12 (0.03-0.53) | .005 |
Treatment failure | ||
Mismatch related vs HLA-identical sibling | 1.23 (0.80-1.89) | .351 |
Other significant risk factors | ||
Disease stage before transplantation | ||
Advanced vs early/intermediate | 3.23 (1.99-5.24) | < .001 |
Disease type | ||
ALL | 1.00 | .015† |
AML | 0.92 (0.55-1.57) | .771 |
CML | 0.55 (0.33-0.94) | .027 |
MDS | 0.29 (0.12-0.74) | .010 |
Overall survival | ||
Mismatch related vs HLA-identical sibling | 1.12 (0.71-1.76) | .620 |
Other significant risk factors | ||
Disease stage before transplantation | ||
Advanced vs early/intermediate | 3.30 (2.00-5.45) | < .001 |
Disease type | ||
ALL | 1.00 | .028† |
AML | 0.85 (0.49-1.50) | .584 |
CML | 0.57 (0.33-0.98) | .043 |
MDS | 0.27 (0.10-0.74) | .011 |
Outcome . | RR (95% CI) . | P . |
---|---|---|
aGVHD | ||
Mismatch related vs HLA-identical sibling | 1.57 (1.06-2.33) | .024 |
Other significant risk factors | ||
Disease stage before transplantation | ||
Advanced vs early/intermediate | 1.68 (1.09-2.60) | .020 |
ABO blood group | ||
Matched | 1.00 | .033† |
Minor mismatched | 0.42 (0.22-0.81) | .009 |
Major mismatched | 0.93 (0.61-1.42) | .733 |
cGVHD | ||
Mismatch related vs HLA-identical sibling | 0.99 (0.72-1.38) | .969 |
TRM* | ||
Mismatch related vs HLA-identical sibling | 1.75 (0.99-3.09) | .054 |
Relapse | ||
Mismatch related vs HLA-identical sibling | 0.86 (0.45-1.65) | .653 |
Other significant risk factors | ||
Disease stage before transplantation | ||
Advanced vs early/intermediate | 5.69 (2.92-11.09) | < .001 |
Disease type | ||
ALL | 1.00 | .002† |
AML | 0.75 (0.36-1.56) | .436 |
CML | 0.24 (0.09-0.59) | .002 |
MDS | 0.12 (0.03-0.53) | .005 |
Treatment failure | ||
Mismatch related vs HLA-identical sibling | 1.23 (0.80-1.89) | .351 |
Other significant risk factors | ||
Disease stage before transplantation | ||
Advanced vs early/intermediate | 3.23 (1.99-5.24) | < .001 |
Disease type | ||
ALL | 1.00 | .015† |
AML | 0.92 (0.55-1.57) | .771 |
CML | 0.55 (0.33-0.94) | .027 |
MDS | 0.29 (0.12-0.74) | .010 |
Overall survival | ||
Mismatch related vs HLA-identical sibling | 1.12 (0.71-1.76) | .620 |
Other significant risk factors | ||
Disease stage before transplantation | ||
Advanced vs early/intermediate | 3.30 (2.00-5.45) | < .001 |
Disease type | ||
ALL | 1.00 | .028† |
AML | 0.85 (0.49-1.50) | .584 |
CML | 0.57 (0.33-0.98) | .043 |
MDS | 0.27 (0.10-0.74) | .011 |